Industry & research collaboration announced: Will teamwork make dream work?

ABLE & FIRM declare partnership with the aim of advancing the commercialization of regenerative medicine

Go to the profile of Adam Price-Evans
Aug 18, 2017
Upvote 0 Comment

The Association of Biotechnology Led Enterprise (ABLE; India) and the Forum for Innovative Regenerative Medicine (FIRM; Japan) have entered in to an industry and research collaboration with the aim of advancing the field of regenerative medicine and gene therapy.

ABLE is a not-for-profit forum representing the Indian Biotechnology Sector, while FIRM is an industry organization with a goal expediting industrialization of regenerative medicine in Japan.

The agreement, termed The Memorandum of Understanding, was signed by P. Manohar (Head of the Committee for Regenerative Medicine Group, ABLE) and Yuzo Toda (Chairman, FIRM) in the presence of Jagdish Prasad and GN Singh (both Government of India), amongst other dignitaries.

The partnership will involve the sharing of information on technology, policy and laws and offers a unique platform to advance the commercialization of potentially life-saving regenerative products in India, Japan and elsewhere.

Manohar stated, “We are proud to be a partner of the prestigious Forum for Innovative Regenerative Medicine (FIRM) in this revolutionary research and industry collaborations. The partnership is a step forward to enhance the learning and training on cell and gene treatment leading to enhancement of the cell and gene therapies which help to address major unmet medical needs in India. We look forward to working with FIRM and contribute towards controlling and curing major human illness.”

“Regenerative medicine and cell & gene therapies are the most noteworthy developing innovation according to medical, biotechnology and pharmaceuticals. Our association with ABLE is an opportunity to work towards the advancement of the field and tap on the potential to transform human healthcare. Through the partnership, we can share learnings and insights to contribute towards curing major human illness,” commented Takuya Yokokawa (FIRM).


Go to the profile of Adam Price-Evans

Adam Price-Evans

Commissioning Editor, Future Science Group , Future Science Group

Commissioning Editor for the journal Regenerative Medicine and editor of RegMedNet. If you have any interest in submitting to the journal Regenerative Medicine or have any queries, please don't hesitate to contact me.

No comments yet.